These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
482 related articles for article (PubMed ID: 11158033)
1. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer. Khosravi J; Diamandi A; Mistry J; Scorilas A J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033 [TBL] [Abstract][Full Text] [Related]
2. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327 [TBL] [Abstract][Full Text] [Related]
3. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening. Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487 [TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Ho PJ; Baxter RC Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044 [TBL] [Abstract][Full Text] [Related]
5. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia. Aksoy Y; Aksoy H; Bakan E; Atmaca AF; Akçay F Urol Int; 2004; 72(1):62-5. PubMed ID: 14730168 [TBL] [Abstract][Full Text] [Related]
6. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Miyata Y; Sakai H; Hayashi T; Kanetake H Prostate; 2003 Feb; 54(2):125-32. PubMed ID: 12497585 [TBL] [Abstract][Full Text] [Related]
7. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml. Zhigang Z; Jieming L; Su L; Wenlu S J Surg Oncol; 2007 Jul; 96(1):54-61. PubMed ID: 17345593 [TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Ho PJ; Baxter RC Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695 [TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. Finne P; Auvinen A; Koistinen H; Zhang WM; Määttänen L; Rannikko S; Tammela T; Seppälä M; Hakama M; Stenman UH J Clin Endocrinol Metab; 2000 Aug; 85(8):2744-7. PubMed ID: 10946875 [TBL] [Abstract][Full Text] [Related]
10. Ratios of IGF-I, IGF binding protein-3, and prostate-specific antigen in prostate cancer detection. Stattin P; Stenman UH; Riboli E; Hallmans G; Kaaks R J Clin Endocrinol Metab; 2001 Dec; 86(12):5745-8. PubMed ID: 11739433 [TBL] [Abstract][Full Text] [Related]
11. Elevated insulin and reduced insulin like growth factor binding protein-3/prostate specific antigen ratio with increase in prostate size in Benign Prostatic Hyperplasia. Sreenivasulu K; Nandeesha H; Dorairajan LN; Rajappa M; Vinayagam V Clin Chim Acta; 2017 Jun; 469():37-41. PubMed ID: 28300542 [TBL] [Abstract][Full Text] [Related]
12. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Platz EA; Pollak MN; Leitzmann MF; Stampfer MJ; Willett WC; Giovannucci E Cancer Causes Control; 2005 Apr; 16(3):255-62. PubMed ID: 15947877 [TBL] [Abstract][Full Text] [Related]
13. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging. Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354 [TBL] [Abstract][Full Text] [Related]
14. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval. Janssen JA; Wildhagen MF; Ito K; Blijenberg BG; Van Schaik RH; Roobol MJ; Pols HA; Lamberts SW; Schröder FH J Clin Endocrinol Metab; 2004 Sep; 89(9):4391-6. PubMed ID: 15356036 [TBL] [Abstract][Full Text] [Related]
15. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461 [TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and prostate cancer: correlation with Gleason score. Correa LL; Neto LV; Lima GA; Gabrich R; Miranda LC; Gadelha MR Int Braz J Urol; 2015; 41(1):110-5. PubMed ID: 25928516 [TBL] [Abstract][Full Text] [Related]
17. Are plasma insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) useful markers of prostate cancer? Lopez JB; Sahabudin RM; Chin LP Int J Biol Markers; 2004; 19(2):164-7. PubMed ID: 15255551 [TBL] [Abstract][Full Text] [Related]
18. Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer. Romppanen J; Haapalainen T; Punnonen K; Penttilä I Anticancer Res; 2002; 22(1A):415-20. PubMed ID: 12017325 [TBL] [Abstract][Full Text] [Related]
19. Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia. Sciarra A; Gentile V; Monti S; Dattilo C; Autran Gomez A; Salciccia S; Pannunzi LP; Toscano V; Di Silverio F Urol Int; 2008; 80(1):68-73. PubMed ID: 18204237 [TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Chokkalingam AP; Pollak M; Fillmore CM; Gao YT; Stanczyk FZ; Deng J; Sesterhenn IA; Mostofi FK; Fears TR; Madigan MP; Ziegler RG; Fraumeni JF; Hsing AW Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):421-7. PubMed ID: 11352850 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]